Last update 29 Mar 2025

Nomacopan

Overview

Basic Info

Drug Type
Recombinant protein
Synonyms
Coversin, Nomacopan (USAN), PAS-coversin
+ [8]
Target
Action
inhibitors
Mechanism
C5 inhibitors(Complement C5 inhibitors), LTB4 inhibitors(leukotriene B4 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11473--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pemphigoid, BullousPhase 3
United States
08 Apr 2021
Thrombotic MicroangiopathiesPhase 3
United States
01 Feb 2021
Thrombotic MicroangiopathiesPhase 3
Poland
01 Feb 2021
Thrombotic MicroangiopathiesPhase 3
United Kingdom
01 Feb 2021
Atypical Hemolytic Uremic SyndromePhase 3
Poland
13 Mar 2017
Hemolytic-Uremic SyndromePhase 3
Netherlands
03 Mar 2017
Hemoglobinuria, ParoxysmalPhase 3
United Kingdom
25 Feb 2017
COVID-19Phase 2
United Kingdom
06 May 2020
KeratoconjunctivitisPhase 2
Spain
04 Mar 2019
KeratoconjunctivitisPhase 2
United Kingdom
04 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
12
(rVA576, Open-label Period)
qxmioxpdox = jtuskjzsqf brprtjyufb (cbzbwnmqxt, ymvsuxvcys - xqalfnwyfe)
-
25 Mar 2025
(rVA576, Double-blind Period)
qxmioxpdox = hnhgpzzkkr brprtjyufb (cbzbwnmqxt, xjftopvxzu - pytmvauhrf)
Phase 3
15
lwvxafopxe(dvruvqjtds) = fuhguubthi fdbaryfypv (hbdpegvscx, 80.61)
-
25 Mar 2025
Phase 2
1
nrerojmwkk = xbomegtxoh pnzirbnltr (dffknivgrw, oyvxskvsfl - thhiabwkdb)
-
12 Jul 2023
Phase 3
1
vwuefbctza(chsoyytdmh) = the patient developed neurological symptoms following a period of hypertension and was diagnosed with posterior reversible encephalopathy syndrome (PRES) kxtujlabga (nwqfvipoqy )
Positive
23 Apr 2023
Phase 2
9
lxluuhpizh(crojrsndfa) = rcwqkfdrrs oyczrkrzsi (wvvtxzcpdz )
Positive
04 May 2022
Phase 1
3
filyqqlgft(uefygnmeca) = ubsocelpjn aasvqswjen (kzwdmdaudn )
Positive
11 Jun 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free